Dolutegravir Sodium (BioDeep_00000673928)
代谢物信息卡片
Dolutegravir Sodium
化学式: C20H18F2N3NaO5 (441.1112162)
中文名称: 度鲁特韦钠盐
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)[O-].[Na+]
InChI: /q
描述信息
D004791 - Enzyme Inhibitors > D019429 - Integrase Inhibitors > D019428 - HIV Integrase Inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents
C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent
同义名列表
1 个代谢物同义名
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:76007
- KEGGdrug: D10113
- PubChem: 46216142
- ChEMBL: CHEMBL1213165
- CAS: 1051375-19-9
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Elisa de Lazzari, Eugenia B Negredo, Pere Domingo, Juan M Tiraboschi, Esteve Ribera, Nadia Abdulghani, Verònica Alba, Salvador Fernández-Arroyo, Consuelo Viladés, Joaquim Peraire, Jose M Gatell, Jose L Blanco, Francesc Vidal, Anna Rull, Esteban Martinez. Multiomics plasma effects of switching from triple antiretroviral regimens to dolutegravir plus lamivudine.
The Journal of antimicrobial chemotherapy.
2024 May; 79(5):1133-1141. doi:
10.1093/jac/dkae083. [PMID: 38546974] - Irene Nakatudde, Elizabeth Katana, Eva Laker Agnes Odongpiny, Esther Alice Nalugga, Barbara Castelnuovo, Mary Glenn Fowler, Philippa Musoke. Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir - based antiretroviral therapy start in Kampala, Uganda.
AIDS research and therapy.
2024 Apr; 21(1):23. doi:
10.1186/s12981-024-00615-6. [PMID: 38637785] - Sergio Sequera-Arquelladas, Carmen Hidalgo-Tenorio, Luis López-Cortés, Alicia Gutiérrez, Jesús Santos, Francisco Téllez, Mohamed Omar, Sergio Ferra-Murcia, Elisa Fernández, Rosario Javier, Coral García-Vallecillos, Juan Pasquau. DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain.
Viruses.
2024 02; 16(2):. doi:
10.3390/v16020259. [PMID: 38400035] - Vianney John Kigongo, Joaniter I Nankabirwa, Freddy Eric Kitutu, Ronald Ssenyonga, Ronald Kasoma Mutebi, Andrew Kazibwe, Ronald Kiguba, Andrew D Kambugu, Barbara Castelnuovo. Dyslipidemia among adult people living with HIV on dolutegravir - based antiretroviral therapy at a private tertiary hospital in Kampala, Uganda: burden and determinants.
BMC infectious diseases.
2024 Jan; 24(1):53. doi:
10.1186/s12879-023-08892-8. [PMID: 38183002] - Kuldeep K Ashta, Sumit Arora, Rajesh Khanna, Nishant Raman, Anirudh Anilkumar, Charu Mohan. A Phase-IV Non-interventional Study to Assess Virological Effectiveness, Safety, and Tolerability of DTG-based Antiretroviral Therapy in HIV-1 Infected Indian Persons Living with HIV.
Current HIV research.
2024; 22(1):31-46. doi:
10.2174/011570162x264021231108010324. [PMID: 38284697] - Yinghua Wei, Jin Li, Ruhong Xu, Li Wen, Yiming Deng, Lixia He, Huijun Zhong, Yanhao Wang. Efficacy and safety profiles of dolutegravir plus lamivudine vs. bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1.
Chinese medical journal.
2023 Nov; ?(?):. doi:
10.1097/cm9.0000000000002907. [PMID: 37914678] - Filippo Lagi, Andrea Giacomelli, Vanni Borghi, Arturo Ciccullo, Lucia Taramasso, Giordano Madeddu, Gabriella D'Ettorre, Andrea Giacometti, Filippo Ducci, Andrea De Vito, Rachele Pincino, Simona Di Giambenedetto, Cristina Mussini, Spinello Antinori, Gaetana Sterrantino. Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
Journal of medical virology.
2023 10; 95(10):e29149. doi:
10.1002/jmv.29149. [PMID: 37805832] - Simone Perazzolo, Zachary Stephen, Masa Eguchi, Xiaolin Xu, Rachele Delle Fratte, Ann C Collier, Ann J Melvin, Rodney J Y Ho. A novel formulation enabled transformation of 3 HIV drugs tenofovir-lamivudine-dolutegravir (TLD) from short-acting to long-acting all-in-one injectable.
AIDS (London, England).
2023 Aug; ?(?):. doi:
10.1097/qad.0000000000003706. [PMID: 37650755] - Alejandro D Bendala-Estrada, Mariana Diaz-Almiron, Carmen Busca, Rafael Mican, Julen Cadiñanos, Maria Luisa Montes, Luz Martin-Carbonero, Eulalia Valencia, Rocío Montejano, Ana Delgado-Hierro, Jose I Bernardino. Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study.
HIV medicine.
2023 05; 24(5):558-567. doi:
10.1111/hiv.13432. [PMID: 36394195] - R Palacios, C Gómez-Ayerbe, J L Casado, F Tejerina, M L Montes, M Castaño, A Ocampo, D Rial, E Ribera, M J Galindo, C Hidalgo, C Fariñas, M Montero, T Payeras, F Fanjul, J de la Torre, J Santos. Efficacy and safety of dolutegravir/rilpivirine in real-world clinical practice. GeSIDA study 1119.
HIV medicine.
2023 Apr; ?(?):. doi:
10.1111/hiv.13489. [PMID: 37016556] - Laura Waters, Lambert Assoumou, Ana González-Cordón, Stefano Rusconi, Pere Domingo, Mark Gompels, Stephane de Wit, François Raffi, Christoph Stephan, Mar Masiá, Jürgen Rockstroh, Christine Katlama, Georg M N Behrens, Graeme Moyle, Margaret Johnson, Julie Fox, Hans-Jürgen Stellbrink, Giovanni Guaraldi, Eric Florence, Stefan Esser, José M Gatell, Anton Pozniak, Esteban Martínez. Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2023 03; 76(5):861-870. doi:
10.1093/cid/ciac827. [PMID: 36259527] - Wantin Sribenjalux, Tharatorn Nuntawit, Atibordee Meesing, Ploenchan Chetchotisakd. Virological outcomes and metabolic effects after switching from ritonavir-boosted protease inhibitors to a dolutegravir-based regimen in virologically suppressed patients living with HIV.
International journal of STD & AIDS.
2023 02; 34(2):98-107. doi:
10.1177/09564624221137972. [PMID: 36378013] - Mohammed Jemal, Tewodros Shibabaw Molla, Markeshaw Tiruneh G Medhin, Endeshaw Chekol Abebe, Tadesse Asmamaw Dejenie. Blood glucose level and serum lipid profiles among people living with HIV on dolutegravir-based versus efavirenz-based cART; a comparative cross-sectional study.
Annals of medicine.
2023; 55(2):2295435. doi:
10.1080/07853890.2023.2295435. [PMID: 38118463] - Eisuke Adachi, Kazuhiko Ikeuchi, Michiko Koga, Hiroshi Yotsuyanagi. Changes in Inflammatory Biomarkers When Switching from Three-Drug Regimens to Dolutegravir Plus Lamivudine in People Living with HIV.
AIDS research and human retroviruses.
2022 12; 38(12):881-883. doi:
10.1089/aid.2022.0115. [PMID: 36301933] - Francesca Lombardi, Simone Belmonti, Davide Moschese, Massimiliano Fabbiani, Alberto Borghetti, Arturo Ciccullo, Elena Visconti, Simona Di Giambenedetto. Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting.
HIV research & clinical practice.
2022 12; 23(1):28-36. doi:
. [PMID: 35758043] - Carmen Hidalgo-Tenorio, David Vinuesa, Coral García-Vallecillos, Leopoldo Muñoz-Medina, Sergio Sequera, Rosario Javier, Miguel Ángel López-Ruz, Svetlana Sadyrbaeva-Dolgova, Juan Pasquau. Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV.
Viruses.
2022 11; 14(12):. doi:
10.3390/v14122626. [PMID: 36560630] - IkRak Jung, Becky Tu-Sekine, Sunghee Jin, Frederick Anokye-Danso, Rexford S Ahima, Todd T Brown, Sangwon F Kim. Dolutegravir Suppresses Thermogenesis via Disrupting Uncoupling Protein 1 Expression and Mitochondrial Function in Brown/Beige Adipocytes in Preclinical Models.
The Journal of infectious diseases.
2022 11; 226(9):1626-1636. doi:
10.1093/infdis/jiac175. [PMID: 35512127] - Olayemi Osiyemi, Stéphane De Wit, Faïza Ajana, Fiona Bisshop, Joaquín Portilla, Jean Pierre Routy, Christoph Wyen, Mounir Ait-Khaled, Peter Leone, Keith A Pappa, Ruolan Wang, Jonathan Wright, Nisha George, Brian Wynne, Michael Aboud, Jean van Wyk, Kimberly Y Smith. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2022 09; 75(6):975-986. doi:
10.1093/cid/ciac036. [PMID: 35079789] - Maria Saumoy, Jose Luís Sánchez-Quesada, Lambert Assoumou, José Maria Gatell, Ana González-Cordón, Giovanni Guaraldi, Pere Domingo, Andrea Giacomelli, Jérôme Connault, Christine Katlama, Mar Masiá, Jordi Ordónez-Llanos, Anton Pozniak, Esteban Martínez, Daniel Podzamczer. Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study.
The Journal of antimicrobial chemotherapy.
2022 06; 77(7):1980-1988. doi:
10.1093/jac/dkac117. [PMID: 35411401] - Amedeo De Nicolò, Andrea Calcagno, Ilaria Motta, Elisa De Vivo, Antonio D'Avolio, Giovanni Di Perri, Lubbe Wiesner, Isma-Eel Ebrahim, Gary Maartens, Catherine Orrell, Helen McIlleron. The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study.
Antimicrobial agents and chemotherapy.
2022 06; 66(6):e0013622. doi:
10.1128/aac.00136-22. [PMID: 35583344] - Aida N Kawuma, Roeland E Wasmann, Kelly E Dooley, Marta Boffito, Gary Maartens, Paolo Denti. Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin.
Antimicrobial agents and chemotherapy.
2022 06; 66(6):e0021522. doi:
10.1128/aac.00215-22. [PMID: 35604212] - Suyash Deodhar, Brady Sillman, Aditya N Bade, Sean N Avedissian, Anthony T Podany, JoEllyn M McMillan, Nagsen Gautam, Brandon Hanson, Bhagya L Dyavar Shetty, Adam Szlachetka, Morgan Johnston, Michellie Thurman, Daniel J Munt, Alekha K Dash, Milica Markovic, Arik Dahan, Yazen Alnouti, Alborz Yazdi, Bhavesh D Kevadiya, Siddappa N Byrareddy, Samuel M Cohen, Benson Edagwa, Howard E Gendelman. Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation.
Nature communications.
2022 Jun; 13(1):3226. doi:
10.1038/s41467-022-30902-7. [PMID: 35680875] - Kenza Ngono Ayissi, Jennifer Gorwood, Laura Le Pelletier, Christine Bourgeois, Carine Beaupère, Martine Auclair, Roberta Foresti, Roberto Motterlini, Michael Atlan, Aurélie Barrail-Tran, Roger Le Grand, Delphine Desjardins, Bruno Fève, Olivier Lambotte, Jacqueline Capeau, Véronique Béréziat, Claire Lagathu. Inhibition of Adipose Tissue Beiging by HIV Integrase Inhibitors, Dolutegravir and Bictegravir, Is Associated with Adipocyte Hypertrophy, Hypoxia, Elevated Fibrosis, and Insulin Resistance in Simian Adipose Tissue and Human Adipocytes.
Cells.
2022 06; 11(11):. doi:
10.3390/cells11111841. [PMID: 35681536] - Nicholas I Paton, Joseph Musaazi, Cissy Kityo, Stephen Walimbwa, Anne Hoppe, Apolo Balyegisawa, Jesca Asienzo, Arvind Kaimal, Grace Mirembe, Abbas Lugemwa, Gilbert Ategeka, Margaret Borok, Henry Mugerwa, Abraham Siika, Eva Laker A Odongpiny, Barbara Castelnuovo, Agnes Kiragga, Andrew Kambugu. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
The lancet. HIV.
2022 06; 9(6):e381-e393. doi:
10.1016/s2352-3018(22)00092-3. [PMID: 35460601] - Abdulafeez Akinloye, Oluwasegun Eniayewu, Babatunde Adeagbo, Oluseye Bolaji, Adeniyi Olagunju. Validation and Clinical Application of a Liquid Chromatography-Ultraviolet Detection Method to Quantify Dolutegravir in Dried Blood Spots.
Therapeutic drug monitoring.
2022 06; 44(3):430-437. doi:
10.1097/ftd.0000000000000929. [PMID: 34629444] - Boris Revollo, Laura Viñuela, Lorena de la Mora, Federico García, Marc Noguera-Julián, Mariona Parera, Roger Paredes, Josep M Llibre. Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression.
The Journal of antimicrobial chemotherapy.
2022 05; 77(6):1738-1740. doi:
10.1093/jac/dkac082. [PMID: 35274144] - Clifford G Banda, Dumisile Nkosi, Elizabeth Allen, Lesley Workman, Mwayiwawo Madanitsa, Marumbo Chirwa, Mayamiko Kapulula, Sharon Muyaya, Steven Munharo, Lubbe Wiesner, Kamija S Phiri, Victor Mwapasa, Feiko O Ter Kuile, Gary Maartens, Karen I Barnes. Effect of dihydroartemisinin/piperaquine for malaria intermittent preventive treatment on dolutegravir exposure in pregnant women living with HIV.
The Journal of antimicrobial chemotherapy.
2022 05; 77(6):1733-1737. doi:
10.1093/jac/dkac081. [PMID: 35288747] - Theodore D Ruel, Edward P Acosta, Jessica P Liu, Kathryn P Gray, Kathleen George, Nicole Montañez, Stephanie Popson, Ann M Buchanan, Mattie Bartlett, Dale Dayton, Patricia Anthony, Cynthia Brothers, Cynthia Vavro, Rajendra Singh, Lucy Koech, Tichaona Vhembo, Blandina T Mmbaga, Jorge A Pinto, Els F M Dobbels, Moherndran Archary, Kulkanya Chokephaibulkit, Pradthana Ounchanum, Jaime G Deville, Rohan Hazra, Ellen Townley, Andrew Wiznia. Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial.
The lancet. HIV.
2022 05; 9(5):e332-e340. doi:
10.1016/s2352-3018(22)00044-3. [PMID: 35489377] - Lucy Campbell, Fowzia Ibrahim, Birgit Barbini, Amanda Samarawickrama, Chloe Orkin, Julie Fox, Laura Waters, Yvonne Gilleece, Shema Tariq, Frank A Post. Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir.
HIV medicine.
2022 04; 23(4):362-370. doi:
10.1111/hiv.13215. [PMID: 34866304] - Laura Labarthe, Thibaut Gelé, Hélène Gouget, Mariam-Sarah Benzemrane, Pauline Le Calvez, Nicolas Legrand, Olivier Lambotte, Roger Le Grand, Christine Bourgeois, Aurélie Barrail-Tran. Pharmacokinetics and tissue distribution of tenofovir, emtricitabine and dolutegravir in mice.
The Journal of antimicrobial chemotherapy.
2022 03; 77(4):1094-1101. doi:
10.1093/jac/dkab501. [PMID: 35022753] - Briony S Chisholm, Annoesjka M Swart, Marc Blockman. South African healthcare workers' knowledge of dolutegravir's drug-drug interactions in the first year of its rollout: a cross-sectional online survey.
Journal of the International AIDS Society.
2022 03; 25(3):e25885. doi:
10.1002/jia2.25885. [PMID: 35255196] - Leonardo Calza, Giorgio Legnani, Ciro Fulgaro, Gabriella Verucchi, Isabella Bon, Tiziana Lazzarotto, Pierluigi Viale. Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/Abacavir.
Journal of acquired immune deficiency syndromes (1999).
2022 03; 89(3):e30. doi:
10.1097/qai.0000000000002861. [PMID: 34743087] - Alice-Andrée Mariaggi, Rebecca Bauer, Caroline Charre, Elise Gardiennet, Vincent Meiffredy, Faiza Ajana, Karine Lacombe, Gilles Pialoux, Eric Cua, Christine Rouzioux, Laurence Meyer, Antoine Cheret, Véronique Avettand-Fenoel. HIV-1-RNA and total HIV-1-DNA loads in the genital compartment in men receiving dolutegravir- versus darunavir-based combined ART (cART) regimens during primary HIV infection.
The Journal of antimicrobial chemotherapy.
2022 02; 77(3):735-739. doi:
10.1093/jac/dkab427. [PMID: 35195692] - Roger T Buju, Pierre Z Akilimali, Erick N Kamangu, Gauthier K Mesia, Jean Marie N Kayembe, Hippolyte N Situakibanza. Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study.
International journal of environmental research and public health.
2022 01; 19(3):. doi:
10.3390/ijerph19031085. [PMID: 35162109] - Cindy Vavro, Theodore Ruel, Andrew Wiznia, Nicole Montañez, Keith Nangle, Joseph Horton, Ann M Buchanan, Eugene L Stewart, Paul Palumbo. Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
Antimicrobial agents and chemotherapy.
2022 01; 66(1):e0164521. doi:
10.1128/aac.01645-21. [PMID: 34694878] - Jade Ghosn, Lambert Assoumou, Caroline Lascoux-Combe, Gilles Peytavin, Karine Amat, Audrey Gabassi, Minh P Le, Robert Nzalakanda, Nadia Valin, Roland Landman, Marie-Laure Chaix, Constance Delaugerre. HIV-1 RNA Kinetics in Blood Plasma and in Seminal Plasma of Men Starting a Dolutegravir-Based Triple-Combination Regimen at the Time of Primary HIV-1 Infection.
The Journal of infectious diseases.
2022 01; 225(1):116-120. doi:
10.1093/infdis/jiab336. [PMID: 34166492] - Maria Mazzitelli, Lolita Sasset, Davide Leoni, Cristina Putaggio, Anna Maria Cattelan. Real life use of dolutegravir doravirine dual regimen in experienced elderly PLWH with multiple comorbidities and on polypharmacy: A retrospective analysis.
Medicine.
2021 Dec; 100(52):e28488. doi:
10.1097/md.0000000000028488. [PMID: 34967394] - Saeed Kalantari, Soheil R Fard, Donya Maleki, Mahshid T Taher, Zeynab Yassin, Yousef Alimohamadi, Sara Minaeian. Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
Journal of medical virology.
2021 12; 93(12):6557-6565. doi:
10.1002/jmv.27195. [PMID: 34255369] - Perrine Courlet, Charlotte Barbieux, Delphine Sculier, Gilles Wandeler, Marcel Stoeckle, Enos Bernasconi, Dominique Braun, Pietro Vernazza, Matthias Cavassini, Annalisa Marinosci, Mikaela Smit, Huldrych F Günthard, Patrick Schmid, Andreas Limacher, Monia Guidi, Susana Alves Saldanha, Laurent Arthur Decosterd, Alexandra Calmy. Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial.
British journal of clinical pharmacology.
2021 11; 87(11):4455-4460. doi:
10.1111/bcp.14832. [PMID: 33764567] - Pierre Frange, Stephane Blanche, Florence Veber, Veronique Avettand-Fenoel. Dolutegravir in the long term in children and adolescents: frequent virological failure but rare acquired genotypic resistance.
HIV medicine.
2021 11; 22(10):958-964. doi:
10.1111/hiv.13154. [PMID: 34369051] - Margherita Bracchi, Nicole Pagani, Alessia Dalla Pria, Ana Milinkovic, Nneka Nwokolo, Lervina Thomas, Sundhyia Mandalia, Marta Boffito, Graeme Moyle. A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients.
HIV research & clinical practice.
2021 10; 22(5):128-139. doi:
. [PMID: 34551678] - Junaid Omar, Izak Loftus, Nabeelah Vallie, Richard B Whitmore, Gaironesa Solomon, Michelle Powell, Samela Mniki, Mosedi Namane. A reflective process led by a family physician to develop a renal-protection surveillance tool for HIV patients newly started on dolutegravir.
African journal of primary health care & family medicine.
2021 Sep; 13(1):e1-e3. doi:
10.4102/phcfm.v13i1.3088. [PMID: 34636616] - Tahir Khuroo, Sathish Dharani, Eman M Mohamed, Sujana Immadi, Zhixing Wu, Mansoor A Khan, Dai Lu, Pramod Nehete, Ziyaur Rahman. Ultra-long acting prodrug of dolutegravir and delivery system - Physicochemical, pharmacokinetic and formulation characterizations.
International journal of pharmaceutics.
2021 Sep; 607(?):120889. doi:
10.1016/j.ijpharm.2021.120889. [PMID: 34271151] - Laura Dickinson, Stephen Walimbwa, Yashna Singh, Julian Kaboggoza, Kenneth Kintu, Mary Sihlangu, Julie-Anne Coombs, Thokozile R Malaba, Josaphat Byamugisha, Henry Pertinez, Alieu Amara, Joshua Gini, Laura Else, Christie Heiberg, Eva Maria Hodel, Helen Reynolds, Landon Myer, Catriona Waitt, Saye Khoo, Mohammed Lamorde, Catherine Orrell. Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2021 09; 73(5):e1200-e1207. doi:
10.1093/cid/ciaa1861. [PMID: 33346335] - Teodora Pene Dumitrescu, Samit R Joshi, Jianfeng Xu, Thomas J Greene, Mark Johnson, Laurie Butcher, Eric Zimmerman, Lindsey Webster, Theresa T Pham, Max Lataillade, Sherene Min. Phase I evaluation of pharmacokinetics and tolerability of the HIV-1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults.
British journal of clinical pharmacology.
2021 09; 87(9):3501-3507. doi:
10.1111/bcp.14759. [PMID: 33533507] - Rajendra P Singh, Kimberly Adkison, Allen Wolstenholme, Judy Hopking, Brian Wynne. Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants.
Clinical pharmacology in drug development.
2021 09; 10(9):985-993. doi:
10.1002/cpdd.996. [PMID: 34265164] - Ana González-Cordón, Lambert Assoumou, Graeme Moyle, Laura Waters, Margaret Johnson, Pere Domingo, Julie Fox, Hans-Jürgen Stellbrink, Giovanni Guaraldi, Mar Masiá, Mark Gompels, Stephane De Wit, Eric Florence, Stefan Esser, François Raffi, Georg Behrens, Anton Pozniak, José M Gatell, Esteban Martínez. Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV.
The Journal of antimicrobial chemotherapy.
2021 08; 76(9):2380-2393. doi:
10.1093/jac/dkab158. [PMID: 34120186] - Haruyuki Hongo, Takako Nagao, Kyoko Nakamura, Tomomi Kitaichi, Yuko Maeno, Teruhisa Tokunaga, Akiko Fukuda, Ichiro Koga. Safety and Effectiveness Analysis of Dolutegravir in Patients with HIV-1: Interim Report of Post-Marketing Surveillance in Japan.
Advances in therapy.
2021 08; 38(8):4480-4504. doi:
10.1007/s12325-021-01842-3. [PMID: 34275116] - Banda Marco, Herrera Cristina, Reynaga Cristhian, Rangel Sigfrido, Josue Del Angel, Angel Reyes, Prudente Isidoro. Dolutegravir in Mexico for special populations: A cost analysis perspective.
AIDS reviews.
2021 07; 23(3):126-132. doi:
10.24875/aidsrev.m21000042. [PMID: 34198310] - Andrea Giacomelli, Federico Conti, Laura Pezzati, Letizia Oreni, Anna Lisa Ridolfo, Valentina Morena, Cecilia Bonazzetti, Gabriele Pagani, Tiziana Formenti, Massimo Galli, Stefano Rusconi. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
BMC infectious diseases.
2021 Jun; 21(1):595. doi:
10.1186/s12879-021-06304-3. [PMID: 34157984] - Juan M Tiraboschi, Jhon Rojas, Henrik Zetterberg, Kaj Blennow, Jordi Niubo, Johanna Gostner, Antonio Navarro-Alcaraz, Camila Piatti, Dietmar Fuchs, Magnus Gisslén, Raul Rigo-Bonnin, Esteban Martinez, Daniel Podzamczer. No Changes in Human Immunodeficiency Virus (HIV) Suppression and Inflammatory Markers in Cerebrospinal Fluid in Patients Randomly Switched to Dolutegravir Plus Lamivudine (Spanish HIV/AIDS Research Network, PreEC/RIS 62).
The Journal of infectious diseases.
2021 06; 223(11):1928-1933. doi:
10.1093/infdis/jiaa645. [PMID: 33049035] - Xiaomei I Liu, Jeremiah D Momper, Natella Y Rakhmanina, Dionna J Green, Gilbert J Burckart, Tim R Cressey, Mark Mirochnick, Brookie M Best, John N van den Anker, André Dallmann. Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir.
Clinical pharmacokinetics.
2021 06; 60(6):795-809. doi:
10.1007/s40262-020-00977-w. [PMID: 33527213] - Shauna H Gunaratne, Hong-Van Tieu, Timothy J Wilkin, Barbara S Taylor. CROI 2021: Advances in Antiretroviral Therapy for HIV and Antiviral Therapy for COVID-19.
Topics in antiviral medicine.
2021 Jun; 29(3):361-378. doi:
NULL. [PMID: 34370418] - Gianmaria Baldin, Arturo Ciccullo, Francesca Lombardi, Anna D'Angelillo, Alex Dusina, Arianna Emiliozzi, Damiano Farinacci, Davide Moschese, Chiara Picarelli, Alberto Borghetti, Simona Di Giambenedetto. Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice.
AIDS research and human retroviruses.
2021 06; 37(6):429-432. doi:
10.1089/aid.2020.0219. [PMID: 33280486] - Daniele Di Carlo, Francesca Falasca, Enrico Palermo, Ivano Mezzaroma, Caterina Fimiani, Guido Siccardi, Luigi Celani, Francesco Maria Di Campli, Gabriella d'Ettorre, Guido Antonelli, Ombretta Turriziani. Dolutegravir-Based Regimen for Maintenance of Viral Suppression in People Living with HIV: 48-Week Results in Real-Life Setting.
AIDS research and human retroviruses.
2021 06; 37(6):478-485. doi:
10.1089/aid.2020.0196. [PMID: 33487130] - Vania Giacomet, Samuel Lazzarin, Andrea Manzo, Laura Paradiso, Katia Maruca, Graziano Barera, Gian Vincenzo Zuccotti, Stefano Mora. Body Fat Distribution and Metabolic Changes in a Cohort of Adolescents Living With HIV Switched to an Antiretroviral Regimen Containing Dolutegravir.
The Pediatric infectious disease journal.
2021 05; 40(5):457-459. doi:
10.1097/inf.0000000000003066. [PMID: 33847293] - Aida N Kawuma, Stephen I Walimbwa, Goonaseelan Colin Pillai, Saye Khoo, Mohammed Lamorde, Roeland E Wasmann, Paolo Denti. Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine.
The Journal of antimicrobial chemotherapy.
2021 04; 76(5):1269-1272. doi:
10.1093/jac/dkab022. [PMID: 33550391] - P D J Bollen, H A B Prins, A Colbers, K Velthoven-Graafland, B J A Rijnders, T E M S de Vries-Sluijs, E van Nood, J Nouwen, H Bax, M de Mendonca Melo, A Verbon, D M Burger, C Rokx. The dolutegravir/valproic acid drug-drug interaction is primarily based on protein displacement.
The Journal of antimicrobial chemotherapy.
2021 04; 76(5):1273-1276. doi:
10.1093/jac/dkab021. [PMID: 33544819] - Guan-Jhou Chen, Hsin-Yun Sun, Sui-Yuan Chang, Aristine Cheng, Yu-Shan Huang, Sung-Hsi Huang, Yi-Chia Huang, Yi-Ching Su, Wen-Chun Liu, Chien-Ching Hung. Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
2021 Apr; 105(?):147-151. doi:
10.1016/j.ijid.2021.02.045. [PMID: 33592339] - Yuki Enoki, Nagomi Kishi, Kazuki Sakamoto, Eri Uchiyama, Yukitaka Hayashi, Norihiro Suzuki, Motoyasu Ito, Kazuaki Taguchi, Yuta Yokoyama, Junko Kizu, Kazuaki Matsumoto. Multivalent cation and polycation polymer preparations influence pharmacokinetics of dolutegravir via chelation-type drug interactions.
Drug metabolism and pharmacokinetics.
2021 Apr; 37(?):100371. doi:
10.1016/j.dmpk.2020.11.006. [PMID: 33556698] - Yi Zheng, Gabrielle Lui, Sana Boujaafar, Radia Aboura, Naïm Bouazza, Frantz Foissac, Jean-Marc Treluyer, Sihem Benaboud, Déborah Hirt, Inès Gana. Development of a simple and rapid method to determine the unbound fraction of dolutegravir, raltegravir and darunavir in human plasma using ultrafiltration and LC-MS/MS.
Journal of pharmaceutical and biomedical analysis.
2021 Mar; 196(?):113923. doi:
10.1016/j.jpba.2021.113923. [PMID: 33571728] - K Priya Dharshini, Hao Fang, D Ramya Devi, Jin-Xuan Yang, Rong-Hua Luo, Yong-Tang Zheng, Marek Brzeziński, B N Vedha Hari. pH-sensitive chitosan nanoparticles loaded with dolutegravir as milk and food admixture for paediatric anti-HIV therapy.
Carbohydrate polymers.
2021 Mar; 256(?):117440. doi:
10.1016/j.carbpol.2020.117440. [PMID: 33483020] - Annalisa Mondi, Eleonora Cimini, Francesca Colavita, Stefania Cicalini, Carmela Pinnetti, Giulia Matusali, Rita Casetti, Markus Maeurer, Alessandra Vergori, Valentina Mazzotta, Roberta Gagliardini, Federico De Zottis, Vincenzo Schininà, Enrico Girardi, Vincenzo Puro, Giuseppe Ippolito, Francesco Vaia, Maria Rosaria Capobianchi, Concetta Castilletti, Chiara Agrati, Andrea Antinori. COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2.
Journal of medical virology.
2021 03; 93(3):1796-1804. doi:
10.1002/jmv.26556. [PMID: 32975842] - David Rial-Crestelo, Rosa de Miguel, Rocío Montejano, Lourdes Dominguez-Dominguez, Paula Aranguren-Rivas, Andrés Esteban-Cantos, Otilia Bisbal, Mireia Santacreu-Guerrero, Mónica Garcia-Alvarez, Belén Alejos, Asunción Hernando, Laura Bermejo-Plaza, Julen Cadiñanos, Mario Mayoral, Juan Miguel Castro, Victoria Moreno, Luz Martin-Carbonero, Rafael Delgado, Rafael Rubio, Federico Pulido, José Ramón Arribas. Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study.
The Journal of antimicrobial chemotherapy.
2021 02; 76(3):738-742. doi:
10.1093/jac/dkaa479. [PMID: 33200210] - Nomathemba C Chandiwana, Matthew Chersich, W D François Venter, Godspower Akpomiemie, Andrew Hill, Bryony Simmons, Shahin Lockman, Celicia M Serenata, Lee Fairlie, Michelle A Moorhouse. Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa.
AIDS (London, England).
2021 02; 35(2):205-211. doi:
10.1097/qad.0000000000002741. [PMID: 33086234] - F Ibrahim, A Samarawickrama, L Hamzah, R Vincent, Y Gilleece, L Waters, S Kegg, B Barbini, L Campbell, F A Post. Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG.
HIV medicine.
2021 02; 22(2):83-91. doi:
10.1111/hiv.12961. [PMID: 32985122] - Pauline Bollen, Jolien Freriksen, Deborah Konopnicki, Katharina Weizsäcker, Carmen Hidalgo Tenorio, José Moltó, Graham Taylor, Irene Alba-Alejandre, Reinout van Crevel, Angela Colbers, David Burger. The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2021 01; 72(1):121-127. doi:
10.1093/cid/ciaa006. [PMID: 32103260] - Yuta Hikichi, Rachel Van Duyne, Phuong Pham, Jennifer L Groebner, Ann Wiegand, John W Mellors, Mary F Kearney, Eric O Freed. Mechanistic Analysis of the Broad Antiretroviral Resistance Conferred by HIV-1 Envelope Glycoprotein Mutations.
mBio.
2021 01; 12(1):. doi:
10.1128/mbio.03134-20. [PMID: 33436439] - Eiko Yamada, Ritsuo Takagi, Hiroshi Moro, Koji Sudo, Shingo Kato. Saliva as a potential matrix for evaluating pharmacologically active dolutegravir concentration in plasma.
PloS one.
2021; 16(2):e0246994. doi:
10.1371/journal.pone.0246994. [PMID: 33600473] - Andrea Calcagno, José Moltó, Alberto Borghetti, Cristina Gervasoni, Maurizio Milesi, Marta Valle, Valeria Avataneo, Chiara Alcantarini, Francesc Pla-Junca, Mattia Trunfio, Antonio D'Avolio, Simona Di Giambenedetto, Dario Cattaneo, Giovanni Di Perri, Stefano Bonora. Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV.
Clinical pharmacokinetics.
2021 01; 60(1):103-109. doi:
10.1007/s40262-020-00916-9. [PMID: 32737820] - Haneesha Mohan, Monica Guzman Lenis, Evelyn Y Laurette, Oscar Tejada, Tanvi Sanghvi, Kit-Yi Leung, Lindsay S Cahill, John G Sled, Paul Delgado-Olguín, Nicholas D E Greene, Andrew J Copp, Lena Serghides. Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels.
EBioMedicine.
2021 Jan; 63(?):103167. doi:
10.1016/j.ebiom.2020.103167. [PMID: 33341441] - Jennifer Gorwood, Christine Bourgeois, Valérie Pourcher, Guillaume Pourcher, Frédéric Charlotte, Matthieu Mantecon, Cindy Rose, Romain Morichon, Michael Atlan, Roger Le Grand, Delphine Desjardins, Christine Katlama, Bruno Fève, Olivier Lambotte, Jacqueline Capeau, Véronique Béréziat, Claire Lagathu. The Integrase Inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and Induce Insulin Resistance in Human/Simian Adipose Tissue and Human Adipocytes.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2020 12; 71(10):e549-e560. doi:
10.1093/cid/ciaa259. [PMID: 32166319] - Purushothaman Indu, Marimuthu Ragavan Rameshkumar, Narasingam Arunagirinathan, Naif Abdullah Al-Dhabi, Mariadhas Valan Arasu, Savarimuthu Ignacimuthu. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
Journal of infection and public health.
2020 Dec; 13(12):1856-1861. doi:
10.1016/j.jiph.2020.10.015. [PMID: 33168456] - Rima K Acosta, Madeleine Willkom, Kristen Andreatta, Hui Liu, Ross Martin, Aiyappa Parvangada, Hal Martin, Sean Collins, Kirsten L White. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
Journal of acquired immune deficiency syndromes (1999).
2020 11; 85(3):363-371. doi:
10.1097/qai.0000000000002454. [PMID: 32701823] - Ana Gonzalez-Cordon, Lambert Assoumou, Miguel Camafort, Monica Domenech, Giovanni Guaraldi, Pere Domingo, Stefano Rusconi, François Raffi, Christine Katlama, Mar Masia, Jose I Bernardino, Maria Saumoy, Anton Pozniak, Jose M Gatell, Esteban Martinez. Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease.
The Journal of antimicrobial chemotherapy.
2020 11; 75(11):3334-3343. doi:
10.1093/jac/dkaa292. [PMID: 32737482] - L Ryom, A Cotter, R De Miguel, C Béguelin, D Podlekareva, J R Arribas, C Marzolini, Pgm Mallon, A Rauch, O Kirk, J M Molina, G Guaraldi, A Winston, S Bhagani, P Cinque, J D Kowalska, S Collins, M Battegay. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0.
HIV medicine.
2020 11; 21(10):617-624. doi:
10.1111/hiv.12878. [PMID: 32885559] - Eva Agnes Odongpiny Laker, Arnold Arinaitwe, Noela Owarwo, Annet Onzia, Benson Nasasira, Abdullah Wailagala, Ivan Kalule, Godwin Anguzu, Agnes Kiragga, Kay Seden, Isaac Lwanga, Barbara Castelnuovo, Rachel Musomba, Mohammed Lamorde. The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women.
Drug safety.
2020 11; 43(11):1133-1140. doi:
10.1007/s40264-020-00974-9. [PMID: 32926356] - Thibaut Gelé, Hélène Gouget, Valérie Furlan, Pierre-Hadrien Becker, Anne-Marie Taburet, Olivier Lambotte, Aurélie Barrail-Tran. Characteristics of Dolutegravir and Bictegravir Plasma Protein Binding: a First Approach for the Study of Pharmacologic Sanctuaries.
Antimicrobial agents and chemotherapy.
2020 10; 64(11):. doi:
10.1128/aac.00895-20. [PMID: 32868324] - Simon Weidlich, Christoph Boesecke, Jochen Schneider, Hartwig H F Klinker, Alexander Zink, Annamaria Balogh, Eva Wolf, Helen Bidner, Christoph D Spinner. Adequate plasma levels of dolutegravir in combination with ritonavir-boosted darunavir: a pharmacokinetic subgroup analysis of the DUALIS study.
The Journal of antimicrobial chemotherapy.
2020 10; 75(10):3082-3084. doi:
10.1093/jac/dkaa234. [PMID: 32634214] - Willem D F Venter, Simiso Sokhela, Bryony Simmons, Michelle Moorhouse, Lee Fairlie, Nkuli Mashabane, Celicia Serenata, Godspower Akpomiemie, Masebole Masenya, Ambar Qavi, Nomathemba Chandiwana, Kaitlyn McCann, Shane Norris, Matthew Chersich, Gary Maartens, Samanta Lalla-Edward, Alinda Vos, Polly Clayden, Elaine Abrams, Natasha Arulappan, Andrew Hill. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
The lancet. HIV.
2020 10; 7(10):e666-e676. doi:
10.1016/s2352-3018(20)30241-1. [PMID: 33010240] - Alexandra Calmy, Tamara Tovar Sanchez, Charles Kouanfack, Mireille Mpoudi-Etame, Sandrine Leroy, Ségolène Perrineau, Martial Lantche Wandji, Darius Tetsa Tata, Pierette Omgba Bassega, Thérèse Abong Bwenda, Marie Varloteaux, Marcel Tongo, Eitel Mpoudi-Ngolé, Alice Montoyo, Noémie Mercier, Vincent LeMoing, Martine Peeters, Jacques Reynes, Eric Delaporte. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.
The lancet. HIV.
2020 10; 7(10):e677-e687. doi:
10.1016/s2352-3018(20)30238-1. [PMID: 33010241] - Ian J Bishop, Alida M Gertz, Boikhutso Simon, Leabaneng Tawe, Kwana Lechiile, Serena Liu, Nicholas Teodoro, Aamirah Mussa, Ava Avalos, Sifelani Malima, Tshego Maotwe, Lesego Mokganya, Carolyn L Westhoff, Chelsea Morroni. Etonogestrel concentrations among contraceptive implant users in Botswana using and not using dolutegravir-based antiretroviral therapy.
Contraception.
2020 09; 102(3):174-179. doi:
10.1016/j.contraception.2020.04.019. [PMID: 32387328] - Biniyam Alemayehu Ayele, Wondwossen Amogne, Lalise Gemechu. HIV-associated neurocognitive disorder and HIV-associated myelopathy in a patient with a preserved CD4, but high viral load-a rarely reported phenomenon: a case report and literature review.
BMC infectious diseases.
2020 Aug; 20(1):574. doi:
10.1186/s12879-020-05297-9. [PMID: 32758161] - Philippa Harris. Highlights of AIDS 2020.
The lancet. HIV.
2020 08; 7(8):e532. doi:
10.1016/s2352-3018(20)30208-3. [PMID: 32763216] - Pauline D J Bollen, Cecilia L Moore, Hilda A Mujuru, Shafic Makumbi, Adeodata R Kekitiinwa, Elisabeth Kaudha, Anna Parker, Godfrey Musoro, Annet Nanduudu, Abbas Lugemwa, Pauline Amuge, James G Hakim, Pablo Rojo, Carlo Giaquinto, Angela Colbers, Diana M Gibb, Deborah Ford, Anna Turkova, David M Burger. Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
The lancet. HIV.
2020 08; 7(8):e533-e544. doi:
10.1016/s2352-3018(20)30189-2. [PMID: 32763217] - Eisuke Adachi, Makoto Saito, Kazuhiko Ikeuchi, Tokio Hoshina, Hiroshi Yotsuyanagi. Cases of coronavirus disease-2019 in HIV-infected transgender women.
AIDS (London, England).
2020 07; 34(9):1435-1436. doi:
10.1097/qad.0000000000002573. [PMID: 32590441] - Junjie Zhu, Xin Tian, Amina I Shehu, Deborah K McMahon, Xiaochao Ma. ABCG2 Deficiency Does Not Alter Dolutegravir Metabolism and Pharmacokinetics.
The Journal of pharmacology and experimental therapeutics.
2020 07; 374(1):38-43. doi:
10.1124/jpet.119.264424. [PMID: 32303561] - Rakan Nasreddine, Eric Florence, Bernard Vandercam, Michel Moutschen, Jean-Christophe Goffard, Paul De Munter, Marc Delforge, Wouter Marinus, Stéphane De Wit. Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.
AIDS (London, England).
2020 07; 34(8):1151-1159. doi:
10.1097/qad.0000000000002533. [PMID: 32287063] - Sai Disha K, Rashmi Puranik, Sudheesh N, Kavitha K, Fajeelath Fathima, Anu K R, Alex Joseph, Anitha J, G Arunkumar, Piya Paul Mudgal. Structure-based identification of small molecules against influenza A virus endonuclease: an in silico and in vitro approach.
Pathogens and disease.
2020 06; 78(4):. doi:
10.1093/femspd/ftaa032. [PMID: 32614388] - Jolien J M Freriksen, Stein Schalkwijk, Angela P Colbers, Khaled Abduljalil, Frans G M Russel, David M Burger, Rick Greupink. Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling.
Clinical pharmacology and therapeutics.
2020 06; 107(6):1352-1361. doi:
10.1002/cpt.1748. [PMID: 31868223] - Chloe Orkin, Edwin DeJesus, Paul E Sax, Jose R Arribas, Samir K Gupta, Claudia Martorell, Jeffrey L Stephens, Hans-Jurgen Stellbrink, David Wohl, Franco Maggiolo, Melanie A Thompson, Daniel Podzamczer, Debbie Hagins, Jason A Flamm, Cynthia Brinson, Amanda Clarke, Hailin Huang, Rima Acosta, Diana M Brainard, Sean E Collins, Hal Martin. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.
The lancet. HIV.
2020 06; 7(6):e389-e400. doi:
10.1016/s2352-3018(20)30099-0. [PMID: 32504574] - Charlotte Charpentier, Gilles Peytavin, François Raffi, Charles Burdet, Roland Landman, Minh P Lê, Christine Katlama, Gilles Collin, Aida Benalycherif, André Cabie, France Mentré, Yazdan Yazdanpanah, Diane Descamps, Véronique Joly. Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial).
The Journal of antimicrobial chemotherapy.
2020 06; 75(6):1611-1617. doi:
10.1093/jac/dkaa035. [PMID: 32091102] - Dario Cattaneo, Salvatore Sollima, Paola Meraviglia, Laura Milazzo, Davide Minisci, Marta Fusi, Carlo Filice, Cristina Gervasoni. Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings.
Drugs in R&D.
2020 Jun; 20(2):155-160. doi:
10.1007/s40268-020-00300-9. [PMID: 32189238] - Joseph Eron, Chien-Ching Hung, Jean-Guy Baril, Jihad Slim, Vicenç Falcó, Johannes Bogner, Franco Maggiolo, Anthony Mills, Jörg Sievers, Choy Y Man, Rimgaile Urbaityte, Mark Underwood, Allan R Tenorio, Keith A Pappa, Brian Wynne, Justin Koteff, Martin Gartland, Kimberly Y Smith, Michael Aboud. Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
Journal of acquired immune deficiency syndromes (1999).
2020 05; 84(1):60-65. doi:
10.1097/qai.0000000000002302. [PMID: 31977595] - Rosa De Miguel, David Rial-Crestelo, Lourdes Dominguez-Dominguez, Rocío Montejano, Andrés Esteban-Cantos, Paula Aranguren-Rivas, Natalia Stella-Ascariz, Otilia Bisbal, Laura Bermejo-Plaza, Mónica Garcia-Alvarez, Belén Alejos, Asunción Hernando, Mireia Santacreu-Guerrero, Julen Cadiñanos, Mario Mayoral, Juan Miguel Castro, Victoria Moreno, Luz Martin-Carbonero, Rafael Delgado, Rafael Rubio, Federico Pulido, José Ramón Arribas. Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).
EBioMedicine.
2020 May; 55(?):102779. doi:
10.1016/j.ebiom.2020.102779. [PMID: 32408111] - Aude Jary, Anne-Geneviève Marcelin, Charlotte Charpentier, Marc Wirden, Minh P Lê, Gilles Peytavin, Diane Descamps, Vincent Calvez. M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients.
The Journal of antimicrobial chemotherapy.
2020 05; 75(5):1290-1293. doi:
10.1093/jac/dkaa019. [PMID: 32065630] - Emilie R Elliot, Megan Neary, Laura Else, Saye Khoo, Graeme Moyle, Daniel F Carr, Xinzhu Wang, Myra Mcclure, Marta Boffito, Andrew Owen. Genetic influence of ABCG2, UGT1A1 and NR1I2 on dolutegravir plasma pharmacokinetics.
The Journal of antimicrobial chemotherapy.
2020 05; 75(5):1259-1266. doi:
10.1093/jac/dkz558. [PMID: 32011683] - Andrea Giacomelli, Valeria Micheli, Dario Cattaneo, Alessandro Mancon, Cristina Gervasoni. Multidrug-resistant HIV viral rebound during early syphilis: a case report.
BMC infectious diseases.
2020 Apr; 20(1):273. doi:
10.1186/s12879-020-04999-4. [PMID: 32264923] - Kassem Bourgi, Cathy A Jenkins, Peter F Rebeiro, Frank Palella, Richard D Moore, Keri N Altoff, John Gill, Charles S Rabkin, Stephen J Gange, Michael A Horberg, Joseph Margolick, Jun Li, Cherise Wong, Amanda Willig, Viviane D Lima, Heidi Crane, Jennifer Thorne, Michael Silverberg, Gregory Kirk, William C Mathews, Timothy R Sterling, Jordan Lake, John R Koethe. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
Journal of the International AIDS Society.
2020 04; 23(4):e25484. doi:
10.1002/jia2.25484. [PMID: 32294337]